Employers across the United States are quietly abandoning pre-employment marijuana testing even as positive test results reach their highest levels in years.
New workforce data from Quest Diagnostics, drawn from roughly eight million tests, shows marijuana positivity in urine testing rose to 4.4%, up from 3.9% in 2021.
Hair testing, which can detect cannabis use up to 90 days prior, revealed a far sharper trend, with around 15% of tests returning positive, representing a nearly 60% jump since 2021.
Random hair screenings produced the most striking figure of all, with 21% of those tested returning a positive result, the highest of any category in the dataset.
A Wall Street Journal report published on 10 July 2026 captured what many employment lawyers had long suspected, finding that employer appetite for cannabis testing is shrinking even as use climbs.
Fisher Phillips partner Todd Logsdon and a 2024 survey of roughly 1,000 employers found that about half no longer test for cannabis pre-hire, citing concerns that doing so reduces the available applicant pool.
Of employers that still conduct pre-hire testing, 44% reported recruiting difficulties linked to the policy, and nearly a quarter said they were considering loosening their approach.
Major corporations including Citigroup, AutoNation, Home Depot, and Amazon have already dropped pre-hire marijuana testing for most positions, according to the Wall Street Journal report.
The legal landscape adds further complexity, with New York barring most employers from testing job applicants for marijuana and at least two dozen states offering some form of employment protection for medical marijuana users, according to the Marijuana Policy Project.
The Trump administration began the process of reclassifying marijuana as a less dangerous drug this spring, potentially moving it off Schedule I, though that rescheduling process remains ongoing and has not been finalised.
Safety-sensitive industries including trucking and construction are considered unlikely to abandon full-panel testing, with hair testing increasingly used to identify longer-term cannabis use rather than just recent impairment.
Employment lawyers are urging businesses to separate safety-sensitive roles from general positions when designing drug-testing policy, rather than applying a single blanket standard across all employees.
Logsdon’s recommendation to shift resources away from pre-hire cannabis screening and toward monitoring for actual on-the-job impairment is being taken seriously as both a legal and recruiting-competitiveness strategy.
However, experts note there is no mature, legally battle-tested standard for impairment testing comparable to the established thresholds used in urine testing, placing a greater burden on employers to identify and act on signs of impairment.
Employers are advised to conduct jurisdiction-specific audits before finalising any national drug policy, given that a one-size-fits-all approach carries liability risks in states with applicant protections.
The broader direction is clear: off-the-clock cannabis use is increasingly tolerated by employers in a manner similar to alcohol, while on-the-clock impairment remains firmly unacceptable across most industries.